Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4118-4128

  Papanikolaou, Xenofon ^a   Johnson, Sarah ^a   Garg, Tarun ^a   Tian, Erming ^a   Tytarenko, Ruslana ^a   Zhang, Qing ^a   Stein, Caleb ^a   Barlogie, Bart ^a   Epstein, Joshua ^a   Heuck, Christoph ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Apoptosis; Artesunate; Caspases; Myeloma; ROS

Indexed keywords

APOPTOSIS INDUCING FACTOR; ARTESUNATE; BORTEZOMIB; ENDONUCLEASE G; IRON; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; MITOCHONDRIAL PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL MEMBRANE PERMEABILITY; CELL STRESS; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; OXIDATION REDUCTION REACTION; PROTEIN LOCALIZATION; DRUG RESISTANCE; METABOLISM; MITOCHONDRION; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

ANTIMALARIALS; APOPTOSIS; ARTEMISININS; DRUG RESISTANCE, NEOPLASM; HUMANS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MULTIPLE MYELOMA; REACTIVE OXYGEN SPECIES; STRESS, PHYSIOLOGICAL;

EID: 84905120248     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1847     Document Type: Article

References (54)

1. Kyle RA. Long-term survival in multiple myeloma. The New England journal of medicine. 1983; 308 (6):314-316.
2. Nair B, van Rhee F, Shaughnessy JD, Jr., Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J and Barlogie B. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010; 115 (21):4168-4173.
3. Zhan F, Barlogie B, Mulligan G, Shaughnessy JD, Jr. and Bryant B. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008; 111 (2):968-969.
4. Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Blade J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2012; 26 (1):149-157.
5. Chen H, Sun B, Pan S, Jiang H and Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anti-cancer drugs. 2009; 20 (2):131-140.
6. Mercer AE, Maggs JL, Sun XM, Cohen GM, Chadwick J, O'Neill PM and Park BK. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. The Journal of biological chemistry. 2007; 282 (13):9372-9382.
7. Cabello CM, Lamore SD, Bair WB, 3rd, Qiao S, Azimian S, Lesson JL and Wondrak GT. The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Investigational new drugs. 2012; 30 (4):1289-1301.
8. Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magne N, et al. A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget. 2013; 4 (4):502-530.
9. Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. The New England journal of medicine. 2008; 358 (17):1829-1836.
10. Miller RS, Li Q, Cantilena LR, Leary KJ, Saviolakis GA, Melendez V, Smith B and Weina PJ. Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study. Malaria journal. 2012; 11:255.
11. Buzzeo R, Enkemann S, Nimmanapalli R, Alsina M, Lichtenheld MG, Dalton WS and Beaupre DM. Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11 (16):6057-6064.
12. Churbanova IY and Sevrioukova IF. Redox-dependent changes in molecular properties of mitochondrial apoptosis-inducing factor. The Journal of biological chemistry. 2008; 283 (9):5622-5631.
13. Strauss G, WesthoffMA, Fischer-Posovszky P, Fulda S, Schanbacher M, EckhoffSM, Stahnke K, Vahsen N, Kroemer G and Debatin KM. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell death and differentiation. 2008; 15 (2):332-343.
14. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G and Schreiber V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry. 2000; 39 (25):7559-7569.
15. Gilliams-Francis KL, Quaye AA and Naegele JR. PARP cleavage, DNA fragmentation, and pyknosis during excitotoxin-induced neuronal death. Experimental neurology. 2003; 184 (1):359-372.
16. Salvioli S, Ardizzoni A, Franceschi C and Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS letters. 1997; 411 (1):77-82.
17. Murphy MP. How mitochondria produce reactive oxygen species. The Biochemical journal. 2009; 417 (1):1-13.
18. Posner GH, McGarvey DJ, Oh CH, Kumar N, Meshnick SR and Asawamahasadka W. Structure-activity relationships of lactone ring-opened analogs of the antimalarial 1,2,4-trioxane artemisinin. Journal of medicinal chemistry. 1995; 38 (4):607-612.
19. Halliwell B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action? Free radical biology & medicine. 1989; 7(6):645-651.
20. Harding DP and Poole-Wilson PA. Calcium exchange in rabbit myocardium during and after hypoxia: effect of temperature and substrate. Cardiovascular research. 1980; 14 (8):435-445.
21. Luanpitpong S, Chanvorachote P, Nimmannit U, Leonard SS, Stehlik C, Wang L and Rojanasakul Y. Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination. Biochemical pharmacology. 2012; 83 (12):1643-1654.
22. Bera S, Greiner S, Choudhury A, Dispenzieri A, Spitz DR, Russell SJ and Goel A. Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis. Neoplasia. 2010; 12 (12):980-992.
23. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E and Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006; 107 (1):257-264.
24. Elmore S. Apoptosis: a review of programmed cell death. Toxicologic pathology. 2007; 35 (4):495-516.
25. Lorenzo HK and Susin SA. Mitochondrial effectors in caspase-independent cell death. FEBS letters. 2004; 557(1-3):14-20.
26. Zhou C, Pan W, Wang XP and Chen TS. Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. Journal of cellular physiology. 2012; 227 (12):3778-3786.
27. Tait SW and Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nature reviews Molecular cell biology. 2010; 11 (9):621-632.
28. Loeffler M, Daugas E, Susin SA, Zamzami N, Metivier D, Nieminen AL, Brothers G, Penninger JM and Kroemer G. Dominant cell death induction by extramitochondrially targeted apoptosis-inducing factor. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2001; 15 (3):758-767.
29. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC, Brothers G, Mak TW, Penninger J, Earnshaw WC and Kroemer G. Two distinct pathways leading to nuclear apoptosis. The Journal of experimental medicine. 2000; 192 (4):571-580.
30. Soldani C and Scovassi AI. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis: an international journal on programmed cell death. 2002; 7 (4):321-328.
31. Lee TJ, Kim EJ, Kim S, Jung EM, Park JW, Jeong SH, Park SE, Yoo YH and Kwon TK. Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells. Molecular cancer therapeutics. 2006; 5 (9):2398-2407.
32. Zhang AY, Yi F, Jin S, Xia M, Chen QZ, Gulbins E and Li PL. Acid sphingomyelinase and its redox amplification in formation of lipid raft redox signaling platforms in endothelial cells. Antioxidants & redox signaling. 2007; 9 (7):817-828.
33. Welch KD, Davis TZ and Aust SD. Iron autoxidation and free radical generation: effects of buffers, ligands, and chelators. Archives of biochemistry and biophysics. 2002; 397 (2):360-369.
34. O'Neill PM, Barton VE and Ward SA. The molecular mechanism of action of artemisinin--the debate continues. Molecules. 2010; 15 (3):1705-1721.
35. Sazanov LA. Respiratory complex I: mechanistic and structural insights provided by the crystal structure of the hydrophilic domain. Biochemistry. 2007; 46 (9):2275-2288.
36. Lartigue L, Kushnareva Y, Seong Y, Lin H, Faustin B and Newmeyer DD. Caspase-independent mitochondrial cell death results from loss of respiration, not cytotoxic protein release. Molecular biology of the cell. 2009; 20 (23):4871-4884.
37. Ricci JE, Munoz-Pinedo C, Fitzgerald P, Bailly-Maitre B, Perkins GA, Yadava N, Scheffler IE, Ellisman MH and Green DR. Disruption of mitochondrial function during apoptosis is mediated by caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell. 2004; 117 (6):773-786.
38. Korshunov SS, Skulachev VP and Starkov AA. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS letters. 1997; 416 (1):15-18.
39. Ishii T, Miyazawa M, Onouchi H, Yasuda K, Hartman PS and Ishii N. Model animals for the study of oxidative stress from complex II. Biochimica et biophysica acta. 2013; 1827 (5):588-597.
40. Turrens JF, Alexandre A and Lehninger AL. Ubisemiquinone is the electron donor for superoxide formation by complex III of heart mitochondria. Archives of biochemistry and biophysics. 1985; 237 (2):408-414.
41. Zhang S and Gerhard GS. Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PloS one. 2009; 4(10):e7472.
42. Wiedemann FR, Vielhaber S, Schroder R, Elger CE and Kunz WS. Evaluation of methods for the determination of mitochondrial respiratory chain enzyme activities in human skeletal muscle samples. Analytical biochemistry. 2000; 279 (1):55-60.
43. McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, Simpson JA, Paw MK, Pimanpanarak M, Mu O, Singhasivanon P, White NJ and Nosten FH. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. The Lancet infectious diseases. 2012; 12 (5):388-396.
44. Copple IM, Mercer AE, Firman J, Donegan G, Herpers B, Wong MH, Chadwick J, Bringela AD, Cristiano ML, van de Water B, Ward SA, O'Neill PM and Park BK. Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarials. Molecular medicine. 2012; 18:1045-1055.
45. Finaurini S, Ronzoni L, Colancecco A, Cattaneo A, Cappellini MD, Ward SA and Taramelli D. Selective toxicity of dihydroartemisinin on human CD34+ erythroid cell differentiation. Toxicology. 2010; 276 (2):128-134.
46. Orlowski RZ. Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer cell. 2013; 24 (3):275-277.
47. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471 (7339):467-472.
48. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138 (4):645-659.
49. Lee JJ, Kong M, Ayers GD and Lotan R. Interaction index and different methods for determining drug interaction in combination therapy. Journal of biopharmaceutical statistics. 2007; 17 (3):461-480.
50. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer research. 2010; 70 (2):440-446.
51. Plummer JL and Short TG. Statistical modeling of the effects of drug combinations. Journal of pharmacological methods. 1990; 23 (4):297-309.
52. O'Brien MC and Bolton WE. Comparison of cell viability probes compatible with fixation and permeabilization for combined surface and intracellular staining in flow cytometry. Cytometry. 1995; 19 (3):243-255.
53. Garg TK and Chang JY. 15-deoxy-delta 12, 14-Prostaglandin J2 prevents reactive oxygen species generation and mitochondrial membrane depolarization induced by oxidative stress. BMC pharmacology. 2004; 4:6.
54. Botto S, Streblow DN, DeFilippis V, White L, Kreklywich CN, Smith PP and Caposio P. IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. Blood. 2011; 117 (1):352-361.